TG Therapeutics (TGTX) Competitors

TG Therapeutics logo
$62.76 -1.75 (-2.71%)
Closing price 04:00 PM Eastern
Extended Trading
$62.75 -0.01 (-0.02%)
As of 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TGTX vs. BIIB, GMAB, ROIV, UTHR, and INCY

Should you buy TG Therapeutics stock or one of its competitors? TG Therapeutics's main competitors and comparable companies include Biogen (BIIB), Genmab A/S (GMAB), Roivant Sciences (ROIV), United Therapeutics (UTHR), and Incyte (INCY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does TG Therapeutics compare to Biogen?

TG Therapeutics (NASDAQ:TGTX) and Biogen (NASDAQ:BIIB) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

TG Therapeutics presently has a consensus price target of $63.00, indicating a potential downside of 2.34%. Biogen has a consensus price target of $254.41, indicating a potential upside of 0.40%. Given Biogen's higher probable upside, analysts plainly believe Biogen is more favorable than TG Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TG Therapeutics
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78
Biogen
1 Sell rating(s)
10 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.67

58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 8.9% of TG Therapeutics shares are owned by insiders. Comparatively, 0.3% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

TG Therapeutics has a beta of 1.89, indicating that its stock price is 89% more volatile than the broader market. Comparatively, Biogen has a beta of 0.1, indicating that its stock price is 90% less volatile than the broader market.

In the previous week, TG Therapeutics had 3 more articles in the media than Biogen. MarketBeat recorded 27 mentions for TG Therapeutics and 24 mentions for Biogen. Biogen's average media sentiment score of 1.33 beat TG Therapeutics' score of 0.42 indicating that Biogen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
TG Therapeutics
7 Very Positive mention(s)
3 Positive mention(s)
12 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Biogen
17 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

TG Therapeutics has a net margin of 11.81% compared to Biogen's net margin of 3.37%. TG Therapeutics' return on equity of 18.82% beat Biogen's return on equity.

Company Net Margins Return on Equity Return on Assets
TG Therapeutics11.81% 18.82% 7.78%
Biogen 3.37%9.38%5.69%

Biogen has higher revenue and earnings than TG Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TG Therapeutics$616.29M15.82$447.18M$0.6697.74
Biogen$9.89B3.79$1.29B$2.34108.29

Summary

TG Therapeutics and Biogen tied by winning 8 of the 16 factors compared between the two stocks.

How does TG Therapeutics compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and TG Therapeutics (NASDAQ:TGTX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

In the previous week, TG Therapeutics had 8 more articles in the media than Genmab A/S. MarketBeat recorded 27 mentions for TG Therapeutics and 19 mentions for Genmab A/S. TG Therapeutics' average media sentiment score of 0.42 beat Genmab A/S's score of -0.15 indicating that TG Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Genmab A/S
3 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
TG Therapeutics
7 Very Positive mention(s)
3 Positive mention(s)
12 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Genmab A/S has higher revenue and earnings than TG Therapeutics. Genmab A/S is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genmab A/S$3.72B8.62$963M$1.1743.91
TG Therapeutics$616.29M15.82$447.18M$0.6697.74

Genmab A/S has a net margin of 16.97% compared to TG Therapeutics' net margin of 11.81%. TG Therapeutics' return on equity of 18.82% beat Genmab A/S's return on equity.

Company Net Margins Return on Equity Return on Assets
Genmab A/S16.97% 13.67% 6.42%
TG Therapeutics 11.81%18.82%7.78%

Genmab A/S presently has a consensus target price of $53.50, indicating a potential upside of 4.15%. TG Therapeutics has a consensus target price of $63.00, indicating a potential downside of 2.34%. Given Genmab A/S's stronger consensus rating and higher possible upside, analysts plainly believe Genmab A/S is more favorable than TG Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genmab A/S
0 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
3.00
TG Therapeutics
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78

Genmab A/S has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.89, meaning that its stock price is 89% more volatile than the broader market.

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 8.9% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

TG Therapeutics beats Genmab A/S on 9 of the 16 factors compared between the two stocks.

How does TG Therapeutics compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and TG Therapeutics (NASDAQ:TGTX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

In the previous week, Roivant Sciences and Roivant Sciences both had 27 articles in the media. Roivant Sciences' average media sentiment score of 0.50 beat TG Therapeutics' score of 0.42 indicating that Roivant Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Roivant Sciences
7 Very Positive mention(s)
3 Positive mention(s)
11 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
TG Therapeutics
7 Very Positive mention(s)
3 Positive mention(s)
12 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Roivant Sciences currently has a consensus target price of $46.64, suggesting a potential upside of 17.98%. TG Therapeutics has a consensus target price of $63.00, suggesting a potential downside of 2.34%. Given Roivant Sciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Roivant Sciences is more favorable than TG Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Roivant Sciences
1 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.79
TG Therapeutics
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78

Roivant Sciences has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.89, indicating that its share price is 89% more volatile than the broader market.

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 8.8% of Roivant Sciences shares are held by company insiders. Comparatively, 8.9% of TG Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

TG Therapeutics has a net margin of 11.81% compared to Roivant Sciences' net margin of -838.21%. TG Therapeutics' return on equity of 18.82% beat Roivant Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Roivant Sciences-838.21% -22.03% -20.55%
TG Therapeutics 11.81%18.82%7.78%

TG Therapeutics has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Roivant Sciences$8.26M3,467.54-$299.77M-$0.63N/A
TG Therapeutics$616.29M15.82$447.18M$0.6697.74

Summary

TG Therapeutics beats Roivant Sciences on 9 of the 15 factors compared between the two stocks.

How does TG Therapeutics compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and TG Therapeutics (NASDAQ:TGTX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

United Therapeutics has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.89, suggesting that its stock price is 89% more volatile than the broader market.

United Therapeutics has a net margin of 38.61% compared to TG Therapeutics' net margin of 11.81%. United Therapeutics' return on equity of 19.18% beat TG Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
United Therapeutics38.61% 19.18% 17.07%
TG Therapeutics 11.81%18.82%7.78%

94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 8.6% of United Therapeutics shares are owned by company insiders. Comparatively, 8.9% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

United Therapeutics has higher revenue and earnings than TG Therapeutics. United Therapeutics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
United Therapeutics$3.18B7.91$1.33B$26.5022.31
TG Therapeutics$616.29M15.82$447.18M$0.6697.74

United Therapeutics presently has a consensus target price of $676.40, indicating a potential upside of 14.42%. TG Therapeutics has a consensus target price of $63.00, indicating a potential downside of 2.34%. Given United Therapeutics' higher probable upside, analysts plainly believe United Therapeutics is more favorable than TG Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
United Therapeutics
1 Sell rating(s)
3 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.69
TG Therapeutics
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78

In the previous week, United Therapeutics had 2 more articles in the media than TG Therapeutics. MarketBeat recorded 29 mentions for United Therapeutics and 27 mentions for TG Therapeutics. United Therapeutics' average media sentiment score of 0.96 beat TG Therapeutics' score of 0.42 indicating that United Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
United Therapeutics
13 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
TG Therapeutics
7 Very Positive mention(s)
3 Positive mention(s)
12 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

United Therapeutics beats TG Therapeutics on 11 of the 17 factors compared between the two stocks.

How does TG Therapeutics compare to Incyte?

TG Therapeutics (NASDAQ:TGTX) and Incyte (NASDAQ:INCY) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

TG Therapeutics has a beta of 1.89, meaning that its share price is 89% more volatile than the broader market. Comparatively, Incyte has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market.

Incyte has higher revenue and earnings than TG Therapeutics. Incyte is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TG Therapeutics$616.29M15.82$447.18M$0.6697.74
Incyte$6.01B4.10$1.29B$1.8864.35

58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 8.9% of TG Therapeutics shares are owned by company insiders. Comparatively, 16.2% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, TG Therapeutics had 9 more articles in the media than Incyte. MarketBeat recorded 27 mentions for TG Therapeutics and 18 mentions for Incyte. Incyte's average media sentiment score of 0.45 beat TG Therapeutics' score of 0.42 indicating that Incyte is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
TG Therapeutics
7 Very Positive mention(s)
3 Positive mention(s)
12 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Incyte
8 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
3 Very Negative mention(s)
Neutral

TG Therapeutics has a net margin of 11.81% compared to Incyte's net margin of 6.71%. TG Therapeutics' return on equity of 18.82% beat Incyte's return on equity.

Company Net Margins Return on Equity Return on Assets
TG Therapeutics11.81% 18.82% 7.78%
Incyte 6.71%7.92%6.12%

TG Therapeutics presently has a consensus price target of $63.00, indicating a potential downside of 2.34%. Incyte has a consensus price target of $132.86, indicating a potential upside of 9.83%. Given Incyte's higher possible upside, analysts plainly believe Incyte is more favorable than TG Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TG Therapeutics
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78
Incyte
0 Sell rating(s)
14 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.44

Summary

TG Therapeutics beats Incyte on 9 of the 17 factors compared between the two stocks.

Get TG Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TGTX vs. The Competition

MetricTG TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$9.49B$4.07B$7.83B$11.75B
Dividend YieldN/A3.64%2.47%4.41%
P/E Ratio95.0924.2434.3430.11
Price / Sales15.3914.858.005.32
Price / Cash23.0221.8921.0222.34
Price / Book15.384.354.763.85
Net Income$447.18M-$24.19M$3.52B$393.14M
7 Day Performance-0.98%-7.26%-5.34%-4.53%
1 Month Performance16.29%-4.96%-3.61%-5.86%
1 Year Performance102.45%-2.87%0.01%-7.78%

TG Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TGTX
TG Therapeutics
1.8622 of 5 stars
$62.76
-2.7%
$63.00
+0.4%
+108.1%$9.49B$616.29M95.09399
BIIB
Biogen
3.0276 of 5 stars
$254.87
+2.6%
$254.41
-0.2%
+51.2%$37.61B$9.89B21.607,500
GMAB
Genmab A/S
2.2674 of 5 stars
$55.80
+4.0%
$53.61
-3.9%
+69.8%$34.40B$3.72B39.653,029
ROIV
Roivant Sciences
2.2333 of 5 stars
$40.67
+4.6%
$46.55
+14.4%
+94.8%$27.61B$8.26MN/A721
UTHR
United Therapeutics
4.7069 of 5 stars
$582.46
+3.6%
$676.40
+16.1%
+26.8%$26.10B$3.18B21.981,400

Related Companies and Tools


This page (NASDAQ:TGTX) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners